Advertisement

Advertisement

Multiple Myeloma
Immunotherapy

Idecabtagene Vicleucel for Heavily Pretreated Patients With Relapsed or Refractory Multiple Myeloma

In the pivotal phase II KarMMa study reported in The New England Journal of Medicine, Nikhil C. Munshi, MD, and colleagues found that the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel produced high response rates in patients with...

Skin Cancer
Immunotherapy

Study Identifies Mechanisms Tied to Immunotherapy Resistance Among Patients With Melanoma

Researchers have created a new technique that may help to uncover mechanisms cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments. Investigators tested their new technique with cancer cells and matching immune cells from patients with melanoma...

Lymphoma
Immunotherapy

Five-Year Outcomes With Tisagenlecleucel in Patients With Relapsed or Refractory B-Cell Lymphomas

As reported in a letter to the editor in The New England Journal of Medicine by Elise A. Chong, MD, and colleagues, long-term follow-up of a single-center trial of tisagenlecleucel showed maintained responses in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ...

bladder cancer
immunotherapy

Tracy L. Rose, MD, on Bladder Cancer: Gemcitabine, Cisplatin, and Pembrolizumab as Neoadjuvant Therapy

Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II results of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy for patients with muscle-invasive bladder cancer. The trial showed this combination treatment is generally safe and may improve pathologic downstaging, but further study is warranted (Abstract 396).

Kidney Cancer
Immunotherapy

KEYNOTE-427: First-Line Pembrolizumab in Advanced Non–Clear Cell Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced non–clear cell renal cell carcinoma. In a separate cohort of the study,...

Breast Cancer
Immunotherapy

I Let Science, Not Emotion, Dictate My Treatment

I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...

Leukemia
Immunotherapy

Genome-Edited Donor-Derived Anti-CD19 CAR T-Cell Therapy Is Active in B-Cell Acute Lymphoblastic Leukemia

Pooled results of two phase I studies, reported in The Lancet by Reuben Benjamin, MBBS, of the Department of Haematological Medicine, King’s College Hospital, London, and colleagues, indicate that the genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product...

Lymphoma
Immunotherapy

B-Cell and T-Cell Non-Hodgkin Lymphomas

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...

Solid Tumors
Immunotherapy
Genomics/Genetics

Responses to Anti–PD-1/PD-L1 Immunotherapy in Patients With MSS Solid Tumors and High Tumor Mutational Burden

In a single-institution study reported in JAMA Oncology, Valero et al found that response rates to anti–PD-1 or anti–PD-L1 treatments in patients with microsatellite-stable (MSS) solid tumors were generally higher among those with high tumor mutational burden (TMB) defined as ≥ 10...

kidney cancer
immunotherapy

Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).

Gynecologic Cancers
Immunotherapy

Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer

In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer...

Gastroesophageal Cancer
Gastrointestinal Cancer
Immunotherapy

Addition of Andecaliximab to mFOLFOX6 in First-Line Treatment of HER2-Negative Advanced Gastric Cancer

As reported in the Journal of Clinical Oncology by Manish A. Shah, MD, and colleagues, the phase III GAMMA-1 trial showed no improvement in overall survival with the addition of andecaliximab to modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) in the first-line treatment of...

Lung Cancer
Immunotherapy

NEOSTAR: Neoadjuvant Nivolumab or Nivolumab/Ipilimumab in Operable NSCLC

The randomized phase II NEOSTAR trial, which examined single-agent and combined neoadjuvant immune checkpoint inhibitor therapy in patients with stage I to III non–small cell lung cancer (NSCLC), found combination therapy produced a significant clinical benefit (as assessed by major pathologic...

Multiple Myeloma
Immunotherapy

DREAMM-2 Analysis: Number of Prior Treatments No Hindrance to Efficacy of Belantamab Mafodotin-blmf

A post hoc analysis of the phase II DREAMM-2 trial showed single-agent belantamab mafodotin-blmf to be efficacious and tolerable in patients with relapsed or refractory multiple myeloma treated with at least three prior therapies, investigators reported at the 2020 American Society of Hematology...

Multiple Myeloma
Immunotherapy

Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma

Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response (VGPR) or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess...

Multiple Myeloma
Immunotherapy

Expert Point of View: Ajay K. Nooka, MD, MPH, FACP

Ajay K. Nooka, MD, MPH, FACP, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be...

Multiple Myeloma
Immunotherapy

New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma

B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH) Annual...

Multiple Myeloma
Immunotherapy

Expert Point of View: Sagar Lonial, MD, FACP

Sagar Lonial, MD, FACP, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial for The ASCO Post. “APOLLO is a highly awaited study, as the use of daratumumab plus...

Multiple Myeloma
Immunotherapy

Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma

The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 The triplet of daratumumab, pomalidomide, and low-dose dexamethasone ...

Lymphoma
Immunotherapy

Expert Point of View: Marco Ruella, MD

Marco Ruella, MD, of Perelman School of Medicine and Scientific Director of the Lymphoma Program, University of Pennsylvania, commented on this study on CD58 aberrations: “This is a very important study because it describes a possible new mechanism for relapse after CAR-T19 immunotherapy in...

Lymphoma
Immunotherapy

Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies

Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to a study presented at the 2020...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other chimeric antigen receptor (CAR) T-cell products being...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...

Leukemia
Immunotherapy

Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL

Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased...

Leukemia
Lymphoma
Multiple Myeloma
Immunotherapy

ASH 2020 Meeting Highlights

The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term stoppages or delays due to the pandemic, the studies presented at the 2020 American Society of...

Breast Cancer
Immunotherapy

Addition of Adjuvant Pertuzumab to Chemotherapy Plus Trastuzumab in Early HER2-Positive Breast Cancer: 6-Year Follow-up of the APHINITY Trial

As reported in the Journal of Clinical Oncology by Martine Piccart, MD, PhD, and colleagues, the preplanned second interim analysis of overall survival in the phase III APHINITY trial showed no significant benefit of the addition of adjuvant pertuzumab to chemotherapy plus trastuzumab after a...

Lymphoma
Immunotherapy

Effect of Organ Function–Based Eligibility Criteria on Clinical Trial Enrollment for Patients With DLBCL

In a study reported in the Journal of Clinical Oncology, Khurana et al found that up to 24% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) receiving standard immunochemotherapy are excluded from participation in clinical trials on the basis of organ function eligibility...

bladder cancer
immunotherapy

Monika Joshi, MD, on Urothelial Cancer of the Bladder: Durvalumab and Radiotherapy for Localized Disease

Monika Joshi, MD, of Penn State Hershey Cancer Institute, discusses phase II results from the DUART study, which explored the efficacy of concurrent durvalumab, a checkpoint inhibitor, and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of the bladder (Abstract 398).

Kidney Cancer
Immunotherapy

KEYNOTE-427: First-Line Pembrolizumab in Advanced Clear Cell Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology by McDermott et al, findings in a cohort of the phase II KEYNOTE-427 study showed that pembrolizumab monotherapy produced durable responses as first-line treatment for advanced clear cell renal cell carcinoma. In a separate cohort of the study,...

Lung Cancer
Immunotherapy

KEYNOTE-598 Trial: Addition of Ipilimumab to Pembrolizumab in Previously Untreated Patients With Metastatic NSCLC and High PD-L1 Expression

As reported in the Journal of Clinical Oncology by Michael Boyer, MBBS, PhD, and colleagues, an interim analysis in the phase III KEYNOTE-598 trial showed no improvement in overall or progression-free survival with the addition of ipilimumab to pembrolizumab in previously untreated patients with...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carcinoma, lenvatinib plus pembrolizumab improved outcomes vs sunitinib. Lenvatinib plus everolimus also improved progression-free survival and overall survival rates vs sunitinib (Abstract 269).

Skin Cancer
Immunotherapy

Fecal Microbiota Transplants May Help Patients With Advanced Melanoma Respond to Immunotherapy

For patients with melanoma who do not respond to treatment with immunotherapy, adjusting the composition of microorganisms in the intestines through the use of fecal transplants may aid in overcoming resistance to therapy. These findings were published by Davar et al in Science. In the study, some...

Bladder Cancer
Immunotherapy

Enfortumab Vedotin-ejfv Prolongs Survival in Patients With Metastatic Urothelial Carcinoma

Treatment with the antibody-drug conjugate enfortumab vedotin-ejfv has been found to significantly increase survival of patients with metastatic urothelial carcinoma, according to results from the phase III EV-301 clinical trial. These findings were presented by Thomas Powles, MD, PhD, and...

bladder cancer
immunotherapy

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to demonstrate a significant survival advantage over standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (Abstract 393).

Multiple Myeloma
Immunotherapy

Achievement and Maintenance of MRD Negativity With Daratumumab-Containing Regimens in Patients With Relapsed or Refractory Multiple Myeloma

In an analysis of the phase III POLLUX and CASTOR trials reported in the Journal of Clinical Oncology, Avet-Loiseau et al found that the addition of daratumumab to standard therapy was associated with higher rates of—and more prolonged—measurable residual disease (MRD) negativity in patients with...

lung cancer
immunotherapy

Martin Reck, MD, PhD, on SCLC: Maintenance Therapy for Patients With Extensive-Stage Disease

Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).

lung cancer
immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease

Martin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unresectable, locally advanced, stage III non–small cell lung cancer (Abstract OA02.03).

Kidney Cancer
Immunotherapy

Nivolumab Plus Cabozantinib Shows Sustained Benefits as First-Line Treatment for Advanced RCC

New analyses from the phase III CheckMate 9ER trial are being presented at the 2021 Genitourinary Cancers Symposium. These new findings demonstrate clinically meaningful, sustained efficacy benefits as well as quality-of-life improvements with the combination of nivolumab and cabozantinib compared...

Lung Cancer
Immunotherapy

Nivolumab/Ipilimumab vs Chemotherapy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma: CheckMate 743 Trial

As reported in The Lancet by Paul Baas, MD, and colleagues, a prespecified interim analysis in the phase III CheckMate 743 trial has shown improved overall survival with first-line nivolumab/ipilimumab vs platinum-based chemotherapy in patients with unresectable malignant pleural mesothelioma. The...

Breast Cancer
Immunotherapy

Expert Point of View: William Gradishar, MD

William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...

Breast Cancer
Immunotherapy

Is Trop-2 Expression Associated With Benefit From Sacituzumab Govitecan-hziy?

The antibody-drug conjugate sacituzumab govitecan-hziy (sacituzumab govitecan) is beneficial in previously treated patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, according to a biomarker analysis of the phase III ASCENT trial.1 Although greater efficacy...

Multiple Myeloma
Immunotherapy

Novel Insights Into Multiple Myeloma

“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other CAR T-cell products being evaluated for indolent...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...

Gastrointestinal Cancer
Immunotherapy

Expert Point of View: John C. Krauss, MD

The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...

Gastrointestinal Cancer
Immunotherapy

Anti–PD-1 Antibody Dostarlimab Active in Mismatch Repair–Deficient Gastrointestinal Tumors

Dostarlimab, a monoclonal antibody targeting PD-1, showed antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported at the 2021 Gastrointestinal Cancers Symposium by Thierry André, MD, of Sorbonne University and Saint-Antoine...

lung cancer
immunotherapy

Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR-mutant disease and the oral selective AXL inhibitor bemcentinib with pembrolizumab in advanced disease (Abstracts OA01.06 and OA01.07).

lung cancer
immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more benefit in terms of efficacy than pembrolizumab plus placebo in first-line therapy for patients with metastatic high PD-L1–expressing non–small cell lung cancer (Abstract PS01.09).

Bladder Cancer
Immunotherapy

CheckMate 274: Adjuvant Nivolumab May Improve Disease-Free Survival in Patients With Muscle-Invasive Urothelial Carcinoma

Treatment with the immunotherapy nivolumab with or without cisplatin-based chemotherapy following radical surgery significantly improved disease-free survival in patients with muscle-invasive urothelial carcinoma, irrespective of their PD-L1 status, according to a study that will be presented by...

Lung Cancer
Immunotherapy

Five-Year Outcomes From the CheckMate 017 and 057 Trials of Nivolumab vs Docetaxel in Previously Treated Patients With NSCLC

In an analysis of the phase III CheckMate 017 and 057 trials in previously treated patients with advanced squamous (017) and nonsquamous (057) non–small cell lung cancer (NSCLC), reported in the Journal of Clinical Oncology, Hossein Borghaei, DO, MS, and colleagues found pooled 5-year overall...

Advertisement

Advertisement

Advertisement